HORIZON THERAPEUTICS

HZNP
Delayed Quote. Delayed  - 09/27 04:00:00 pm
109.96USD -0.37%
Valuation
Fiscal Period: December 2020 2021
Capitalization1 16 14524 839
Entreprise Value (EV)1 15 06825 911
P/E ratio 40,4x63,6x
Yield --
Capitalization / Revenue 7,34x8,00x
EV / Revenue 6,85x8,34x
EV / EBITDA 15,1x20,2x
Price to Book -5,64x
Nbr of stocks (in thousands) 220 710225 893
Reference price (USD) 73,2110
Announcement Date 02/24/2021-
Previous period Next period
1 USD in Million
Estimates
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2020 2021
Net sales1 2 2003 107
EBITDA1 9991 286
Operating profit (EBIT)1 9961 278
Operating Margin 45,2%41,1%
Pre-Tax Profit (EBT) 402-
Net income1 390409
Net margin 17,7%13,2%
EPS2 1,811,73
Dividend per Share2 --
Announcement Date 02/24/2021-
Previous period Next period
1 USD in Million
2 USD
Finances - Leverage
Fiscal Period: December 2020 2021
Net Debt1 -1 072
Net Cash position1 1 077-
Leverage (Debt / EBITDA) -1,08x0,83x
Free Cash Flow1 386910
ROE (Net Profit / Equities) 27,6%26,9%
Shareholders' equity1 1 4111 524
ROA (Net Profit / Asset) 16,3%14,6%
Assets1 2 3882 807
Book Value Per Share2 -19,5
Cash Flow per Share2 2,584,37
Capex1 17028,6
Capex / Sales 7,72%0,92%
Announcement Date 02/24/2021-
Previous period Next period
1 USD in Million
2 USD
Financial Ratios
Size 2021e 2022e
Capitalization 24 839 M $ -
Entreprise Value (EV) 25 911 M $ 24 623 M $
Valuation 2021e 2022e
P/E ratio (Price / EPS) 63,6x 26,2x
Capitalization / Revenue 8,00x 6,54x
EV / Revenue 8,34x 6,82x
EV / EBITDA 20,2x 15,7x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 5,64x 4,72x
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) 41,1% 43,3%
Operating Leverage (Delta EBIT / Delta Sales) 0,69x 1,29x
Net Margin (Net Profit / Revenue) 13,2% 26,3%
ROA (Net Profit / Asset) 14,6% 15,8%
ROE (Net Profit / Equities) 26,9% 26,1%
Rate of Dividend - -
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   0,92% 0,56%
Cash Flow / Sales 31,8% 40,3%
Capital Intensity (Assets / Sales) 0,90x 1,67x
Financial Leverage (Net Debt / EBITDA) 0,83x -
Price Earning Ratio
Change in Enterprise Value/EBITDA
EPS & Dividend